Adaptimmune Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2015 - 2019
Revenue	65.09	178.03	60.28	27.15	6.15	3.96	Upgrade
Revenue Growth (YoY)	-53.99%	195.34%	122.05%	341.50%	55.36%	252.76%	Upgrade
Cost of Revenue	128.69	149.13	126.51	127.73	111.09	91.57	Upgrade
Gross Profit	-63.61	28.9	-66.23	-100.58	-104.94	-87.61	Upgrade
Selling, General & Admin	84.26	81.31	64.46	63.39	57.31	45.8	Upgrade
Operating Expenses	84.26	81.31	64.46	63.39	57.31	45.8	Upgrade
Operating Income	-147.87	-52.41	-130.69	-163.97	-162.25	-133.41	Upgrade
Interest Expense	-5.67	-3.35	-	-	-	-	Upgrade
Interest & Investment Income	5.02	6.6	5.96	1.54	1.1	2.31	Upgrade
Currency Exchange Gain (Loss)	-1.18	-1.73	-0.81	-0.54	3.85	1.11	Upgrade
Other Non Operating Income (Expenses)	-	-	-	-	-0.01	-0.03	Upgrade
EBT Excluding Unusual Items	-149.69	-50.89	-125.54	-162.96	-157.31	-130.02	Upgrade
Merger & Restructuring Charges	-5.95	-5.95	-9.05	-	-	-	Upgrade
Gain (Loss) on Sale of Investments	-	-	-	-	0.01	0.09	Upgrade
Asset Writedown	-10.4	-10.4	-	-	-	-	Upgrade
Other Unusual Items	-	-	22.05	-	-	-	Upgrade
Pretax Income	-166.05	-67.24	-112.54	-162.96	-157.3	-129.93	Upgrade
Income Tax Expense	3.71	3.58	1.34	2.5	0.79	0.16	Upgrade
Net Income	-169.76	-70.81	-113.87	-165.46	-158.09	-130.09	Upgrade
Net Income to Common	-169.76	-70.81	-113.87	-165.46	-158.09	-130.09	Upgrade
Shares Outstanding (Basic)	258	252	201	161	156	142	Upgrade
Shares Outstanding (Diluted)	258	252	201	161	156	142	Upgrade
Shares Change (YoY)	8.53%	25.48%	24.73%	3.47%	9.37%	35.72%	Upgrade
EPS (Basic)	-0.66	-0.28	-0.57	-1.03	-1.01	-0.91	Upgrade
EPS (Diluted)	-0.66	-0.30	-0.57	-1.03	-1.02	-0.91	Upgrade
Free Cash Flow	-191.67	-74.09	-145.56	-171.27	2.16	-55.93	Upgrade
Free Cash Flow Per Share	-0.74	-0.29	-0.72	-1.06	0.01	-0.39	Upgrade
Gross Margin	-97.73%	16.23%	-109.86%	-	-	-	Upgrade
Operating Margin	-227.19%	-29.44%	-216.81%	-603.97%	-2638.58%	-3370.52%	Upgrade
Profit Margin	-260.82%	-39.78%	-188.90%	-609.46%	-2570.99%	-3286.81%	Upgrade
Free Cash Flow Margin	-294.49%	-41.62%	-241.47%	-630.86%	35.05%	-1413.14%	Upgrade
EBITDA	-137.24	-41.18	-120.85	-157.89	-155.68	-125.81	Upgrade
EBITDA Margin	-210.86%	-23.13%	-200.48%	-	-	-	Upgrade
D&A For EBITDA	10.63	11.23	9.84	6.08	6.57	7.59	Upgrade
EBIT	-147.87	-52.41	-130.69	-163.97	-162.25	-133.41	Upgrade
EBIT Margin	-227.19%	-29.44%	-216.81%	-	-	-	Upgrade
Revenue as Reported	65.09	178.03	60.28	27.15	6.15	3.96	Upgrade

Updated Aug 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q